Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Final Results from UKALL60+ (NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia

Bela Patel Wrench, Amy A. Kirkwood, Krisztina Zuborne Alapi, Laura Clifton-Hadley, SooWah Lee, David I. Marks, Anthony V. Moorman, Nicholas J. Morley, Pip Patrick, Zaynab Rana, Clare J. Rowntree, John A. Snowden, Adele K. Fielding

Blood (2022) 140 (Supplement 1): 6125–6126.

https://doi.org/10.1182/blood-2022-159958

Published: 2022

Journal Articles

Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Luke Coyle, MBBS, FRACP, FRCPA, Nicholas J. Morley, Alessandro Rambaldi, MD, Kylie D. Mason, MBBS, MD FRACP, FRCPA, PhD, Gregor Verhoef, MD PhD, Caroline Furness, Rajendra Desai, Noemi Mergen, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-141117

Published: 2020

Journal Articles

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Deborah A. Katz, MD, Michael P. Chu, Kevin A. David, MD, Catherine Thieblemont, MD PhD, Nicholas J. Morley, Sharif S. Khan, Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González-Barca, MD PhD

Blood (2019) 134 (Supplement_1): 4077.

https://doi.org/10.1182/blood-2019-121708

Published: 2019

Journal Articles

Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials

Thomas Creasey, MBBS, Emilio Barretta, Amy A. Kirkwood, MSc, Claire Schwab, PhD, Pip Patrick, PhDMSc,MA, Laura Clifton-Hadley, PhDBSc, Bela Wrench, MBBS, MD MRCP, FRCPath, Tobias F Menne, MD PhD FRCPath, Andrew K McMillan, FRCP, Nicholas J. Morley, John A Snowden, BSc (Hons), MBChB, MD FRCP, FRCPath, Christine J. Harrison, PhD FRCPath, Daniel A. Leongamornlert, PhD, Elli Papaemmanuil, PhD, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David I Marks, MBBS, PhD FRCPath, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Anthony V. Moorman

Blood (2019) 134 (Supplement_1): 2746.

https://doi.org/10.1182/blood-2019-124395

Published: 2019

Journal Articles

Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Luke Coyle, Nicholas J. Morley, Alessandro Rambaldi, MD, Kylie D. Mason, MBBS, MD FRACP, FRCPA, PhD, Gregor Verhoef, MDPhD, Caroline Furness, Alicia Zhang, A. Scott Jung, Janet L. Franklin

Blood (2018) 132 (Supplement 1): 400.

https://doi.org/10.1182/blood-2018-99-112280

Published: 2018

Journal Articles

Outcomes of Patients with Haematological Malignancies Admitted to Either High Dependency Unit (HDU) or Intensive Care Unit (ICU) with or without Haemopoeitic Stem Cell Transplantation (HSCT): Analysis of Prognostic Factors for Survival

Youssef Sorour, Stephen J Webber, Josh G Wright, Nicholas J Morley, John T Reilly, Christopher D Dalley, John A Snowden

Blood (2008) 112 (11): 2391.

https://doi.org/10.1182/blood.V112.11.2391.2391

Published: 2008

NARROW

Final Results from UKALL60+ (NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia

Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials

Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Outcomes of Patients with Haematological Malignancies Admitted to Either High Dependency Unit (HDU) or Intensive Care Unit (ICU) with or without Haemopoeitic Stem Cell Transplantation (HSCT): Analysis of Prognostic Factors for Survival

Email alerts

ASH Publications

American Society of Hematology

Final Results from UKALL60+ (NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia

Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials

Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Outcomes of Patients with Haematological Malignancies Admitted to Either High Dependency Unit (HDU) or Intensive Care Unit (ICU) with or without Haemopoeitic Stem Cell Transplantation (HSCT): Analysis of Prognostic Factors for Survival

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only